SCHEMBL7690157

SCHEMBL7690157

O=c1[nH]ccn1Cc1ccc(Br)nc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.47
GRM2 Q14416 1/20 0.38
PARP1 P09874 1/20 0.37
DBH P09172 10/20 0.37
TRPV6 Q9H1D0 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
BLM P54132 1/20 0.36
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7690163 0.79 DBH (0.45) CYP11B1DBHALDH1A1CYP1A2POLB
SCHEMBL27281887 0.72 CNOT7 (0.43) CYP11B1DBHALDH1A1CYP1A2POLB
SCHEMBL8583692 0.72 DBH (0.45) DBHALDH1A1CYP1A2POLBCYP3A4
SCHEMBL4101771 0.72 DBH (0.62) DBHALDH1A1CYP1A2POLBCYP3A4
SCHEMBL27629494 0.70 KDM4E (0.49) GRM2DBHALDH1A1POLBLMNA
SCHEMBL23121198 0.69 LMNA (0.68) CYP11B1GRM2ALDH1A1POLBLMNA
SCHEMBL29700587 0.69 LMNA (0.68) CYP11B1GRM2ALDH1A1POLBLMNA
SCHEMBL21382645 0.69 CYP11B1 (0.44) CYP11B1DBHALDH1A1CYP1A2POLB
SCHEMBL28015673 0.69 DBH (0.68) DBHALDH1A1CYP1A2POLBCYP3A4
SCHEMBL27629395 0.68 PTPN1 (0.48) ALDH1A1CYP1A2POLBCYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6492397-B1 SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE PHARMACIA CORPORATION 2002-12-10 US disclosed
EP-0664802-B1 N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-03-15 EP disclosed
EP-0579766-B1 N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 1999-06-02 EP disclosed
EP-0508393-B1 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders SEARLE & CO (US) 1999-06-02 EP disclosed
US-5861420-A ANGIOTENSIN II ANTAGONISTS G. D. SEARLE & CO. (US) 1999-01-19 US disclosed
US-5643906-A LOWERING INTRAOCULAR PRESSURE FOR TREATMENT OF GLAUCOMA G.D. SEARLE & CO. (US) 1997-07-01 US disclosed
US-5451592-A Angiotensin antagonist C.D. SEARLE & CO. (US) 1995-09-19 US disclosed
US-5441970-A Administering angiotensin II antagonists to treat congestive heart failure or hypertension G. D. SEARLE & CO. (US) 1995-08-15 US disclosed
EP-0664803-A1 N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1995-08-02 EP disclosed
EP-0664802-A1 N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1995-08-02 EP disclosed
WO-1994008990-A1 N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-04-28 WO disclosed
WO-1994008989-A1 N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-04-28 WO disclosed
EP-0579766-A1 N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-01-26 EP disclosed
US-5164403-A Hypotensive agents, cardiovascular disorders G. D. SEARLE & CO. (US) 1992-11-17 US disclosed
WO-1992017469-A2 N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1992-10-15 WO disclosed
EP-0508393-A1 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders G.D. Searle & Co. (US) 1992-10-14 EP disclosed